A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Brinter and LED Tailor Partner

To implement an automatic photon disinfection system in the 3D bioprinter chamber

Bioprinting startup Brinter has today announced a partnership with LED Tailor to introduce a new disinfecting blue light feature embedded in its multi-material 3D bioprinting solution Brinter®. The system enables the safe production of e.g. tissue models and drugs, and minimizes the need for separate cleanrooms, making bioprinters more portable and safe.

Brinter is a modular bioprinter that is able to print multi-material and highly complex tissue structures in 3D, providing advanced features needed for bioprinting. The device can print both stiff and soft materials, including but not limited to liquids and hydrogels with living cells, bio-paste, metal with binder material, and thermoplastics, while being easy to set up in a lab in minutes.

Blue light is a part of the visible light spectrum, from 400 nm to approximately 500 nm wavelength. Disinfecting blue light, while being completely safe for human beings, kills all forms of bacteria, yeast, and mold. Opposite to UV-light (100–400nm), visible blue light does not deteriorate materials or cause other hazardous effects.

The discovery that all microbes contain blue light-sensitive compounds inside their cells as a part of their natural metabolism has been the key to creating this effective disinfection system.

When these light-sensitive compounds are exposed to specific wavelengths of disinfecting blue light with a certain light intensity, a destructive chemical reaction starts. The end products of this reaction are reactive oxygen radicals inside the microbial cell. Reactive oxygen species (ROS) are molecules containing a very reactive oxygen component, which has the ability to cause damage to any structure inside the microbial cell and destroy it from the inside.

“Our photon disinfection innovation is an automatic and sustainable solution to microbe problems. The system enables safe bioprinting, production of food and beverages, restrains epidemics, and answers the needs of cleanrooms. Our solutions improve safety and vitality of employees and reduce microbiological and chemical risks in healthcare and industrial sites,” says Harri Rautio, CEO at LED Tailor.

“The partnership with LED Tailor makes Brinter the first 3D bioprinter in the world using blue light disinfection technology that can be utilized both inside and outside of the device to clean the environment around the bioprinter,” says Tomi Kalpio, CEO at Brinter.

Customers of Brinter include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, University of Turku, Åbo Akademi, Tampere University, and the University of Helsinki.

To date, Brinter is currently active in over 10 countries, including the USA, Germany, India, and the UK. Last month, the company recently launched its new entry-level model, Brinter Core.

SourceBrinter
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy